ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 24

Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk

Katherine Liao1, Carol J. Etzel2,3, Jeffrey D. Greenberg4, Hongshu Guan5, Joel Kremer6 and Daniel H. Solomon7, 1Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, 2Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, 3Corrona, LLC, Southborough, MA, 4New York University School of Medicine, New York, NY, 5Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 6The Center for Rheumatology, Albany Medical College, Albany, NY, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, functional status, prednisolone, prednisone, prevention and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Session Title: Epidemiology and Public Health - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based on RA characteristics.  The published and internally validated Expanded Risk Score for CVD in RA (ERS-RA) may provide useful information for CVD management.  The ERS-RA identified 3 modifiable RA factors at baseline which were predictive of future CV risk: prednisone use, functional status as defined by the health assessment questionnaire disability index (HAQ-DI), and the clinical disease activity index (CDAI).  We examined whether changes after baseline in these modifiable RA factors correlate with changes in CVD risk.

Methods: Using data from a large RA registry of 15,711 subjects recruited from rheumatology practices in North America, we categorized 10-year risk of CVD using the ERS-RA.  We then used Cox proportional hazards regression to determine if adding information on RA factors during follow-up, had effects on relative risk of CV events (MI, stroke, CV death). Changes in the three modifiable factors were categorized as follows: prednisone use was noted as unchanged, increased if daily dose was increased by at least 25%, or decreased if lowered by at least 25%; HAQ-DI score were categorized as unchanged, increased if higher by at least 0.5 units, or reduced if lowered by at least 0.5; and CDAI was categorized as unchanged, increased if higher by at least 25%, or decreased if lower by 25%.  Cox proportional hazards models were fit using updated information on the three RA factors using information updated every six months. Hazard ratios were estimated worsened or improved values, compared with no change from baseline.

Results: Median follow-up in this cohort was 34 months with 53,861 person-years of follow-up.  During this period, 342 CV events were confirmed for an overall incidence rate of 6.35 per 1,000 person-years (95% CI 5.71 -7.06).  The Table illustrates the considerable changes in RA factors after baseline, with more than half of subjects demonstrating changes in CDAI, 30% in prednisone use, and 26% in HAQ-DI.  Multivariable hazard ratios demonstrate a 30% reduction in CV risk for subjects with reduction in HAQ-DI (95% CI 0.46 – 1.06) and a 56% increase in risk for subjects with increased prednisone dosage (95% CI 1.12 – 2.16).

Conclusion: Cardiovascular risk appears to be modifiable for patients with RA. These preliminary analyses suggest that improvements in HAQ-DI score and reduced prednisone dose may be associated with reduced CV risk overtime.  If confirmed, this information may provide useful evidence for constructing CV risk management recommendations specific to RA.


Disclosure: K. Liao, None; C. J. Etzel, Corrona, LLC, 3,Merck Pharmaceuticals, 9; J. D. Greenberg, Corroma, LLC, 1,Corrona, LLC, 3,AstraZeneca, Celgene, Genentech, Janssen, Novartis and Pfizer, 5; H. Guan, None; J. Kremer, Abbvie, Amgen, BMS, Genentech, GSK, Lilly, Novartis,Pfizer, 5,Abbvie, Genentech, Lilly, Novartis, Pfizer, 2,Genentech (non-promotional only, 8,Corrona, 1,Corrona, 3; D. H. Solomon, Amgen, Lilly, Pfizer, AstraZeneca, Bristol Myers Squibb, Roche/Genentech, Corrona, 2,Uptodate, 7.

To cite this abstract in AMA style:

Liao K, Etzel CJ, Greenberg JD, Guan H, Kremer J, Solomon DH. Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/modifiable-rheumatoid-arthritis-factors-and-impact-on-cardiovascular-risk/. Accessed May 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modifiable-rheumatoid-arthritis-factors-and-impact-on-cardiovascular-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.